UC San Francisco #LIINC study on SCV2 protein persistence up to 14 mon post-COVID in The Lancet Infectious Diseases .

Now need to study this systematically in larger cohorts to pin down what it means. Does it have consequences? #LongCOVID ?

Thanks PolyBio NIH for support

thelancet.com/journals/lanin…

New research: Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised trial

thelancet.com/journals/lanin…

New personal view: The emergence of artemisinin partial resistance in Africa: how do we respond?

thelancet.com/journals/lanin…

#ChatGPT can polish your English but is not a good #reviewer
Excellent Editorial by The Lancet Infectious Diseases
thelancet.com/journals/lanin…

Where are we with #EndTB ? #WorldTBDay

Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021

thelancet.com/journals/lanin…

New comment: Post-tuberculosis lung disease: is there a light at the end of tunnel?

#WorldTBDay

thelancet.com/journals/lanin…

New review: The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience

#WorldTBDay

thelancet.com/journals/lanin…

New comment: Mycobacterium tuberculosis transmission: the importance of precision

#WorldTBDay

thelancet.com/journals/lanin…

New review: Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK

thelancet.com/journals/lanin…